Cyclic nucleotide phosphodiesterase 7B mRNA: an unfavorable characteristic in chronic lymphocytic leukemia.

Cyclic nucleotide phosphodiesterase 7B mRNA: an unfavorable characteristic in chronic lymphocytic leukemia.
复制标题

DOI:
10.1002/ijc.25785
复制
发表时间:
2011-09-01
影响因子:
6.4
通讯作者:
Insel, Paul A.
Insel, Paul A.
中科院分区:
医学1区
文献类型:
--
作者:
Zhang, Lingzhi;Murray, Fiona;Rassenti, Laura Z.;Pu, Minya;Kelly, Colleen;Kanter, Joan R.;Greaves, Andrew;Messer, Karen;Kipps, Thomas J.;Insel, Paul A.

文献摘要

参考文献

相似文献

A cost- and time-efficient means to define the prognosis of patients with chronic lymphocytic leukemia (CLL) is desirable but does not yet exist. Based on evidence that CLL cells have enhanced expression of the cyclic nucleotide phosphodiesterase isoform 7B (PDE7B), we hypothesized that PDE7B expression might provide such information. We assessed PDE7B mRNA expression using quantitative real-time PCR (QPCR) in peripheral blood mononuclear cells isolated from 85 patients and 30 normal subjects. We compared PDE7B mRNA expression with that of other disease features to determine if its expression correlates with the prognosis of patients with CLL. We found that CLL patients with PDE7B mRNA levels in the top quartile (>9-fold elevation relative to normal controls) have a several-year shorter median time-to-treatment (TTT, 36 months) compared to that of patients whose CLL cells express lower levels of PDE7B mRNA (TTT, 77 months, P=0.001). High PDE7B mRNA expression correlates with expression of Zeta-chain-associated protein kinase 70 (ZAP-70), unmutated immunoglobulin heavy chain variable (IGHV) region genes and β2 microglobulin (β2M), but use of a multivariate Cox model revealed that high PDE7B mRNA expression independently predicts a short TTT, even after adjusting for several other disease characteristics (ZAP-70 or CD38 expression, IGHV mutation status, Rai status). High expression of PDE7B is an unfavorable characteristic in CLL. Assessment of PDE7B mRNA expression thus appears to be a clinically useful biomarker to define the prognosis of patients with CLL.
DOI: 10.4049/jimmunol.0804255
发表时间: 2009-05-01
期刊: Journal of immunology (Baltimore, Md. : 1950)
影响因子: --
作者:
Meyers JA;Su DW;Lerner A
通讯作者: Lerner A
DOI: 10.1016/j.beha.2009.12.005
发表时间: 2010-03-01
影响因子: 2.1
作者:
Bertilaccio, M. T. S.;Scielzo, C.;Caligaris-Cappio, F.
通讯作者: Caligaris-Cappio, F.
DOI: 10.4161/cbt.7.2.5262
发表时间: 2008-02-01
影响因子: 3.6
作者:
Chen, Jiezhong;McMillan, Nigel A. J.
通讯作者: McMillan, Nigel A. J.
DOI: 10.1182/asheducation-2002.1.193
发表时间: 2002-01-01
期刊: Hematology. American Society of Hematology. Education Program
影响因子: --
作者:
Kay, Neil E;Hamblin, Terry J;Lin, Thomas
通讯作者: Lin, Thomas
DOI: 10.1016/j.jcv.2007.09.011
发表时间: 2008-02-01
影响因子: 8.8
作者:
Noordhoek, Gerda T.;Weel, Jan Fl.;Brandenburg, Afke H.
通讯作者: Brandenburg, Afke H.